- Stocks
- Pharma & Healthcare
- Samrat Pharma
Samrat Pharma share price
NSE: SAMRATPHPharma & HealthcareChemicals
Samrat Pharma at a glance
With a market capitalisation of ₹61 Cr, it ranks 2966th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Chemicals.
Its return on equity was 9.9% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹72 Cr (+0.8% year on year) and net profit −₹2 Cr, on a standalone basis. Promoters held 49.09% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹61 CrRank 2966 on NSE
- Price to book
- 1.35×FY25
- EPS (TTM)
- −₹10.72to Q4 FY26
- ROE
- 9.9%FY25
- ROCE
- 14.7%FY25
- Debt to equity
- 0.14FY25
- Net profit margin
- 2.5%FY25
- Book value / share
- ₹232.39FY25
- Dividend payout
- 4.3%FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Samrat Pharma quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹81 Cr | ₹70 Cr | ₹64 Cr | ₹71 Cr | ₹76 Cr | ₹79 Cr | ₹63 Cr | ₹72 Cr |
| Revenue YoY | +40.6% | −12.0% | +3.2% | −13.9% | −6.4% | +12.4% | −0.4% | +0.8% |
| Net profit | ₹2 Cr | ₹3 Cr | ₹3 Cr | −₹0 Cr | −₹0 Cr | −₹1 Cr | −₹0 Cr | −₹2 Cr |
| Net profit YoY | +239.3% | — | +717.6% | −128.6% | −111.1% | −122.2% | −116.5% | — |
| Net margin | 2.6% | 3.8% | 4.4% | −0.6% | −0.3% | −0.7% | −0.7% | −2.8% |
| EPS | ₹6.68 | ₹8.61 | ₹9.01 | −₹1.29 | −₹0.74 | −₹1.90 | −₹1.49 | −₹6.59 |
Samrat Pharma financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹137 Cr | ₹179 Cr | ₹222 Cr | ₹311 Cr | ₹282 Cr | ₹286 Cr |
| Operating profit | ₹6 Cr | ₹7 Cr | ₹24 Cr | ₹23 Cr | ₹3 Cr | ₹10 Cr |
| Net profit | ₹4 Cr | ₹5 Cr | ₹17 Cr | ₹17 Cr | ₹2 Cr | ₹7 Cr |
| EPS (₹) | ₹13.71 | ₹17.26 | ₹55.62 | ₹53.83 | ₹7.00 | ₹23.02 |
| Cash from operations | −₹1 Cr | ₹5 Cr | ₹18 Cr | −₹9 Cr | ₹9 Cr | −₹10 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹24 Cr | ₹30 Cr | ₹47 Cr | ₹63 Cr | ₹65 Cr | ₹72 Cr |
Samrat Pharma shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% | 49.09% |
| Foreign institutions | 3.24% | — | 3.24% | 3.24% | 3.24% | 3.24% |
| Non-institutions | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% | 47.67% |
Samrat Pharma vs peers
The listed Pharma & Healthcare companies nearest to Samrat Pharma by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| SUNLOCSunil Health | ₹65.00 | 0.00% | — | ₹67 Cr | 16.6 | — |
| SAMRATPHSamrat Pharma | — | — | — | ₹61 Cr | — | — |
| ROYALRoyal Sense | — | — | — | ₹59 Cr | — | — |
| BACPHARBacil Pharma | — | — | — | ₹58 Cr | — | — |
| VEERHEALTHVeerhealth Care | — | — | — | ₹58 Cr | — | — |
| CONSTRONICConstronics Inf | — | — | — | ₹57 Cr | — | — |
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
Ask anything about Samrat Pharma
Pivot answers on the live chart with evidence you can check, and tests strategies against SAMRATPH's own history. Try: “Why has SAMRATPH moved over the last three months?” · “Backtest a 50-day moving-average crossover on SAMRATPH over five years” · “Compare SAMRATPH with SUNLOC on margins and valuation”
Frequently asked questions about Samrat Pharma
What is the market cap of Samrat Pharma?
Samrat Pharma's market capitalisation is ₹61 Cr (₹61 Cr) at the 22 Oct 2026 close, ranking 2966th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Samrat Pharma?
Return on equity was 9.9% in FY25 and return on capital employed was 14.7% in FY25 (standalone figures).
Is Samrat Pharma a debt-free company?
No. Samrat Pharma's debt-to-equity ratio was 0.14 in FY25, with total debt of ₹0 Cr.
What were Samrat Pharma's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Samrat Pharma reported revenue of ₹72 Cr, +0.8% year on year, and net profit of −₹2 Cr.
What is the shareholding pattern of Samrat Pharma?
As of 30 Jun 2026: promoters 49.09%, foreign institutions 3.24%, non-institutions 47.67%.
Who are Samrat Pharma's competitors?
The listed Pharma & Healthcare companies closest to Samrat Pharma by market cap are Sunil Health, Royal Sense, Bacil Pharma, Veerhealth Care, Constronics Inf and Kabra Drugs.
Is Samrat Pharma a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Samrat Pharma's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SAMRATPH against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text